Vacas-Córdoba Enrique, Climent Núria, De La Mata Francisco J, Plana Montserrat, Gómez Rafael, Pion Marjorie, García Felipe, Muñoz-Fernández Maria Ángeles
Laboratorio InmunoBiología Molecular, Sección Inmunologia, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria del Gregorio Marañón, C/Dr. Esquerdo 46, 28007, Madrid, Spain.
Nanomedicine (Lond). 2014 Dec;9(17):2683-702. doi: 10.2217/nnm.14.172.
Although the antiretroviral therapy has led to a long-term control of HIV-1, it does not cure the disease. Therefore, several strategies are being explored to develop an effective HIV vaccine, such as the use of dendritic cells (DCs). DC-based immunotherapies bear different limitations, but one of the most critical point is the antigen loading into DCs. Nanotechnology offers new tools to overcome these constraints. Dendrimers have been proposed as carriers for targeted delivery of HIV antigens in DCs. These nanosystems can release the antigens in a controlled manner leading to a more potent specific immune response. This review focuses on the first steps for clinical development of dendrimers to assess their safety and potential use in DC-based immunotherapies against HIV.
尽管抗逆转录病毒疗法已实现对HIV-1的长期控制，但并不能治愈该疾病。因此，人们正在探索多种策略来开发有效的HIV疫苗，例如使用树突状细胞（DC）。基于DC的免疫疗法存在不同的局限性，但最关键的一点之一是将抗原载入DC。纳米技术提供了克服这些限制的新工具。树枝状大分子已被提议作为在DC中靶向递送HIV抗原的载体。这些纳米系统可以以可控方式释放抗原，从而引发更强有力的特异性免疫反应。本综述重点关注树枝状大分子临床开发的初步步骤，以评估其安全性以及在基于DC的HIV免疫疗法中的潜在用途。
